Is protracted low-dose temozolomide feasible in glioma patients?
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16476947.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients. This schedule could lead to DNA repair enzyme O6-alkylguanine-DNA alkyltransferase depletion, contributing to overcoming drug resistance. Although Phase III studies are forthcoming, no data are available on the long-term toxicity of temozolomide, which, in this series, incurred prolonged, cumulative lymphopenia, which leads to a high incidence of infections.
Medical subject headings
- Antineoplastic Agents, Alkylating
- Central Nervous System Neoplasms
- Dacarbazine
- Glioma
- Lymphopenia